SYM FINANCIAL Corp Trims Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

SYM FINANCIAL Corp trimmed its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 6.9% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 944 shares of the biopharmaceutical company’s stock after selling 70 shares during the period. SYM FINANCIAL Corp’s holdings in Alnylam Pharmaceuticals were worth $308,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Bessemer Group Inc. raised its stake in shares of Alnylam Pharmaceuticals by 176.9% in the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 69 shares during the period. Crossmark Global Holdings Inc. acquired a new position in Alnylam Pharmaceuticals during the 1st quarter worth approximately $275,000. Strs Ohio acquired a new position in Alnylam Pharmaceuticals during the 1st quarter worth approximately $7,781,000. GAMMA Investing LLC grew its holdings in Alnylam Pharmaceuticals by 14.3% during the 1st quarter. GAMMA Investing LLC now owns 616 shares of the biopharmaceutical company’s stock worth $166,000 after acquiring an additional 77 shares in the last quarter. Finally, Brighton Jones LLC acquired a new position in Alnylam Pharmaceuticals during the 4th quarter worth approximately $243,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have commented on ALNY shares. UBS Group boosted their price target on shares of Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the stock a “buy” rating in a report on Friday, August 1st. Wells Fargo & Company boosted their price target on shares of Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the stock an “equal weight” rating in a report on Friday, August 1st. Morgan Stanley upped their target price on shares of Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the company an “equal weight” rating in a report on Monday, October 6th. JPMorgan Chase & Co. lowered their target price on shares of Alnylam Pharmaceuticals from $475.00 to $473.00 and set an “overweight” rating for the company in a report on Monday, October 13th. Finally, Bank of America upped their target price on shares of Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the company a “buy” rating in a report on Wednesday, September 17th. Twenty-three analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $466.92.

Alnylam Pharmaceuticals Stock Up 3.3%

ALNY stock opened at $478.58 on Tuesday. The company has a fifty day moving average price of $459.70 and a 200 day moving average price of $363.44. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $495.55. The company has a market cap of $62.73 billion, a price-to-earnings ratio of -193.76 and a beta of 0.36. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating the consensus estimate of ($0.54) by $0.86. The firm had revenue of $773.69 million during the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. Alnylam Pharmaceuticals’s revenue for the quarter was up 17.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director Dennis A. Ausiello sold 31,448 shares of the company’s stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $436.58, for a total transaction of $13,729,567.84. Following the completion of the transaction, the director owned 911 shares in the company, valued at approximately $397,724.38. This represents a 97.18% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Colleen F. Reitan sold 18,000 shares of the company’s stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $467.60, for a total transaction of $8,416,800.00. Following the transaction, the director owned 775 shares of the company’s stock, valued at approximately $362,390. The trade was a 95.87% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 98,144 shares of company stock worth $44,160,261 in the last 90 days. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.